Helen Of Troy news

The company is accused of misleading investors about Project Pegasus's effectiveness and financial impact. Actual results showed a 49% EPS decline and 20%+ revenue guidance cut, resulting in a 27.7% stock price drop. The lawsuit alleges the company lacked resources to achieve stated goals while assuring investors of progress.

Company is accused of making false and misleading statements regarding Project Pegasus, failing to disclose that the project would not achieve promised savings and efficiency gains. This represents alleged fraud and misrepresentation to investors, resulting in artificial stock inflation.

The company is accused of misleading investors about Project Pegasus's effectiveness and financial impact. Actual results showed a 49% EPS decline and 20%+ revenue guidance cut, resulting in a 27.7% stock price drop. The allegations suggest management misrepresented the project's progress and the company's financial capacity to achieve stated goals.

The company is accused of making materially false and misleading statements about Project Pegasus, overstating its benefits while concealing implementation failures and lack of resources. This represents alleged securities fraud and breach of investor trust.

The company is the subject of a securities class action lawsuit alleging material misrepresentations about Project Pegasus restructuring efforts. The stock experienced significant corrective declines (27.7% single-day drop) and a $414.4 million goodwill impairment, indicating serious operational and financial issues that were misrepresented to investors.

The company is accused of making false and misleading statements to investors regarding its Project Pegasus restructuring initiative, allegedly overstating progress and cost savings while concealing implementation problems. This resulted in investor losses and triggered a securities fraud class action lawsuit.

Company is accused of misleading investors about restructuring project effectiveness, failed to deliver promised cost savings, reported significant revenue declines (11% and 8.9% year-over-year), massive goodwill impairment of $414.4 million, and stock price declined sharply (22.7% and 25%) following disclosure of underperformance.

Company faces class action lawsuit for alleged securities fraud; announced significant financial deterioration including 49% EPS decline, 20%+ revenue outlook reduction, $414.4 million goodwill impairment, and consecutive stock price drops of 28%, 23%, and 25% following poor quarterly results.

The company is the subject of a securities class action lawsuit alleging misrepresentations about Project Pegasus performance. Despite acknowledging implementation issues, management allegedly misled investors about the program's progress and cost savings, resulting in investor damages when the true details emerged.

The company is accused of making false and misleading statements about Project Pegasus cost-saving initiatives while lacking adequate resources to achieve stated goals. Subsequent financial disclosures revealed a 49% EPS decline and 20%+ revenue guidance cut, resulting in a 27.7% stock price drop and triggering a class action lawsuit.

The company is subject to a securities class action lawsuit with documented substantial stock price declines (27.7%, 22.7%, and 25% on separate dates) resulting in cumulative investor losses of $38.62 per share, indicating potential disclosure or operational issues during the class period.

The company is the subject of a securities class action lawsuit alleging misrepresentations about Project Pegasus performance. Investors claim they suffered damages due to false or misleading statements about the restructuring program's success, despite acknowledged implementation problems.

The company is accused of misleading investors about Project Pegasus's ability to deliver efficiency improvements when it lacked adequate resources. Subsequent earnings disclosures revealed significant underperformance with 11% and 8.9% sales declines, 60% and 51% EPS drops, and a $414.4 million goodwill impairment, resulting in substantial stock price declines of 22.7% and 25%.

The company is the subject of a securities class action lawsuit alleging misrepresentations about Project Pegasus performance. Investors claim they were misled about the success of a restructuring program despite acknowledged implementation problems, resulting in damages when the true details became public.

The company experienced a severe 24.99% stock price decline due to disappointing financial results including significant year-over-year sales decline (8.9%), substantial operating losses ($13.44 GAAP diluted loss per share), and sharp deterioration in adjusted earnings ($0.59 vs. $1.21 prior year), indicating deep operational distress and triggering a securities fraud investigation.

The company reported significant financial deterioration including 8.9% sales decline, substantial losses, and a 24.99% stock price drop. Additionally, the company is now subject to a securities fraud investigation by a major law firm, indicating serious concerns about potential misconduct or misrepresentation to investors.

Company has not yet reported results. Expected to post earnings of $0.51 per share (down 13.6% year-over-year) with revenues of $441.45 million (up 2.2%). Consensus EPS estimate has remained unchanged over the last 30 days, indicating stable but modest expectations.

The company is involved in an upcoming securities class action lawsuit, suggesting allegations of misconduct or misleading disclosures that harmed investors.

A class action lawsuit has been announced on behalf of purchasers of the company's common stock, indicating alleged securities violations.

Subject of securities fraud investigation by Pomerantz LLP, indicating potential unlawful business practices or securities violations, though specific details are not provided in the article.